Navigation Links
Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
Date:11/28/2008

Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has signed a biomanufacturing services agreement with Minnesota-based Biomedical Frontiers Incorporated for the production of an iron chelating agent used in the treatment of thalassemia, an inherited blood disorder.

Toronto, ON (PRWEB) November 28, 2008 - Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has signed a biomanufacturing services agreement with Minnesota-based Biomedical Frontiers Incorporated for the production of an iron chelating agent used in the treatment of thalassemia, an inherited blood disorder.

Therapure Biopharma will apply experience gained previously in the production of Biomedical Frontiers' deferoxamine conjugates, which are injectable iron-binding drugs used to neutralize iron build-up in the blood of patients with an iron overload disorder. Biomedical Frontiers believes that their product offers advantages over existing treatments for thalassemia that will result in improved patient compliance and therefore better clinical outcomes.

In addition to manufacturing clinical trial supplies, Therapure Biopharma will provide debt financing that will partially support Biomedical Frontiers' Phase II clinical program for the product. The contract also gives Therapure Biopharma long-term commercial manufacturing rights when the product is approved by regulators.

"Production of this compound for Biomedical Frontiers is a great example of the flexibility of our modern biomanufacturing facility," said Thomas Wellner. "We are able to produce the necessary supplies of their compound quickly to support the continuing clinical development of this important new product."

"We previously contracted with Therapure Biopharma in the manufacture of drug material to support our successful development program", said Bo Erik Hedlund, President and Chief Executive Officer of Biomedical Frontiers. "Because of this earlier experience, we are very confident in Therapure Biopharma's ability to produce a high-quality product within the timelines we need to start our Phase II trials. Securing both a manufacturer and a financial contribution from Therapure Biopharma will make it much easier for us to acquire the additional funding we need to complete these studies and bring a more effective and user-friendly treatment for thalassemia and other iron overload disorders to markets."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com

About Biomedical Frontiers, Incorporated:

Biomedical Frontiers Incorporated ("BMF or the Company") is a privately held biopharmaceutical company with a focus on developing innovative iron-binding drugs for the treatment of iron overload disorders and acute iron poisoning. BMF's proprietary technical platform involves chemical coupling of drugs to biocompatible polymers. The Company is currently preparing for a Phase II clinical trial for its proprietary lead iron-binding drug, starch-conjugated deferoxamine, in patients with transfusion dependent thalassemia.

For more information, please contact: Bo Hedlund, Ph.D. 612-281-4033

###

Read the full story at http://www.prweb.com/releases/2008/11/prweb1675504.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Therapure Biopharma Inc. opens for business with first client contracts
2. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
3. Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
9. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- Allergan plc (NYSE: AGN ) a leading global ... Allergan,s CEO and President, will be featured as the ... RBC Capital Markets Healthcare Conference on Tuesday, February 23, ... Palace Hotel in New York, NY ... be accessed on Allergan,s Investor Relations web site at ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
(Date:2/10/2016)... Mateo, CA (PRWEB) , ... February 10, 2016 ... ... of Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads ... September 2014. More than 1,600 participants have joined the PROMPT study, which seeks ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an ... treatment of Alzheimer’s disease, announced today it has been selected to present at the ... Breakers in Palm Beach, Florida. The purpose of the Forum is to help ...
Breaking Biology Technology:
(Date:2/9/2016)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... ended December 31, 2015.  --> ... million, an increase of 61% compared to $4.3 million in the ... 2015 was $2.6 million compared to $0.2 million in the fourth ... Higher revenue and operating income in the fourth quarter of ...
(Date:2/5/2016)... Feb. 5, 2016 ... the "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition ... 2016-2020" report to their offering. ... ) has announced the addition of the ...
(Date:2/3/2016)... , February 3, 2016 ... new market research report "Automated Fingerprint Identification System Market ... Latent Search), Application (Banking & Finance, Government, Healthcare, and ... by MarketsandMarkets, the market is expected to be worth ... of 21.0% between 2015 and 2020. The transformation and ...
Breaking Biology News(10 mins):